Top

BMC Public Health

Published in:

Open Access 01-12-2024 | Type 2 Diabetes | Research

Severity of adipose tissue dysfunction is associated with progression of pre-diabetes to type 2 diabetes: the Tehran Lipid and Glucose Study

Authors: Mohammad Jalali, Zahra Bahadoran, Parvin Mirmiran, Fereidoun Azizi, Farhad Hosseinpanah

Published in: BMC Public Health | Issue 1/2024

Abstract

Background

The association of prediabetes (Pre-DM) regression and progression with visceral adiposity index (VAI) and adipose tissue dysfunction (ATD) remains to be investigated.

Methods

The present cohort study was conducted within the framework of the Tehran Lipid and Glucose Study (TLGS) on 1458 Pre-DM cases (aged ≥ 21 years) who were followed for nine years. VAI was estimated based on waist circumference, body mass index, triglycerides, and high-density lipoprotein cholesterol. ATD status (i.e., absent, mild-moderate, and severe) was defined based on the age-stratified cutoff values of VAI. Multinomial logistic regression models with adjustment of potential confounders were used to estimate the chance of Pre-DM regression to normoglycemia or progression to T2D across ATD status.

Results

During the study follow-up, 39.0% of the participants developed T2D, and 37.7% returned to normoglycemia. Compared to mild-moderate ATD, Pre-DM subjects with severe ATD had a higher risk of developing T2D by 45% (OR = 1.45, 95% CI = 11.08–1.93). Severe ATD was also associated with a decreased chance of returning to normoglycemia by 26% (OR = 0.74, 95% CI = 0.55–0.99). Participants with severe ATD had significantly higher fasting (overall mean = 111, 95% CI = 109–112 vs. 106, 95% CI = 105–108 mg/dL) and 2h-serum glucose (overall mean = 165, 95% CI = 161–168 vs. 153, 95% CI = 149–156 mg/dL) concentrations over time.

Conclusion

Severe ATD was associated with an elevated risk of developing T2D and longitudinal poor-glycemic controls in Pre-DM subjects. ATD may be a simple and useful index for detecting subjects at a higher risk of Pre-DM progression to T2D, allowing for timely intervention strategies.

Rooney MR, Fang M, Ogurtsova K, Ozkan B, Echouffo-Tcheugui JB, Boyko EJ, Magliano DJ, Selvin EJDC. Global prevalence of prediabetes. Diabetes Care. 2023. https://doi.org/10.2337/dc22-2376:dc222376.10.2337/dc22-2376.CrossRefPubMed

DeJesus RS, Breitkopf CR, Rutten LJ, Jacobson DJ, Wilson PM, Sauver JS. Incidence rate of prediabetes progression to diabetes: modeling an optimum target group for intervention. Popul Health Manag. 2017;20(3):216–23. https://doi.org/10.1089/pop.2016.0067.CrossRefPubMed

Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet (London, England). 2012;379(9833):2279–90. https://doi.org/10.1016/s0140-6736(12)60283-9.CrossRefPubMed

Modi A, Gadhavi R, Pérez CM, Joshipura K. Longitudinal association between adiposity measures and regression of prediabetes/diabetes. Nutr Metab Cardiovasc Dis. 2021;31(11):3085–94. https://doi.org/10.1016/j.numecd.2021.07.005.CrossRefPubMedPubMedCentral

Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150–9. https://doi.org/10.1001/2012.jama.11132.CrossRefPubMedPubMedCentral

Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Gil MJ, Valentí V, Rotellar F, Ramírez B, Salvador J, et al. Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI. Obesity. 2011;19(7):1439–44. https://doi.org/10.1038/oby.2011.36.CrossRefPubMed

Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–2. https://doi.org/10.2337/dc09-1825.CrossRefPubMedPubMedCentral

Zhou C, Zhang Y, Yang S, He P, Wu Q, Ye Z, Liu M, Zhang Y, Li R, Liu C, et al. Associations between visceral adiposity index and incident nephropathy outcomes in diabetic patients: Insights from the ACCORD trial. Diabetes Metab Res Rev. 2023;39(3): e3602. https://doi.org/10.1002/dmrr.3602.CrossRefPubMed

Zhou C, Zhang Z, Liu M, Zhang Y, He P, Li Q, Xie D, Liang M, Wang G, Nie J. Association of visceral adiposity index with new-onset type 2 diabetes and impaired fasting glucose in hypertensive Chinese adults. Eat Weight Disord-Stud Anorexia, Bulimia Obes. 2022;27:505. https://doi.org/10.1007/s40519-021-01187-4:1-10.10.1007/s40519-021-01187-4.CrossRef

10.

Mousapour P, Barzin M, Valizadeh M, Mahdavi M, Azizi F, Hosseinpanah F. Predictive performance of lipid accumulation product and visceral adiposity index for renal function decline in non-diabetic adults, an 8.6-year follow-up. Clin Experiment Nephrol. 2020;24(3):225–34. https://doi.org/10.1007/s10157-019-01813-7.CrossRef

11.

Amato MC, Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J Endocrinol. 2014;2014:730827. https://doi.org/10.1155/2014/730827.CrossRefPubMedPubMedCentral

12.

Amato MC, Giordano C, Pitrone M, Galluzzo A. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011;10:183. https://doi.org/10.1186/1476-511x-10-183.CrossRefPubMedPubMedCentral

13.

Bozorgmanesh M, Hadaegh F, Azizi F. Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: type 2 diabetes. Lipids Health Dis. 2011;10:88. https://doi.org/10.1186/1476-511x-10-88.CrossRefPubMedPubMedCentral

14.

Bagheri A, Khosravy T, Moradinazar M, Nachvak SM, Pasdar Y, Soleimani D, Samadi M. Optimal cut-off points of fat mass index and visceral adiposity index associated with type 2 diabetes mellitus. Food Sci Nutr. 2022;10(8):2710–7. https://doi.org/10.1002/fsn3.2874.CrossRefPubMedPubMedCentral

15.

Chen C, Xu Y, Guo ZR, Yang J, Wu M, Hu XS. The application of visceral adiposity index in identifying type 2 diabetes risks based on a prospective cohort in China. Lipids Health Dis. 2014;13:108. https://doi.org/10.1186/1476-511x-13-108.CrossRefPubMedPubMedCentral

16.

Bahadoran Z, Mirmiran P, Shabani M, Azizi F. Higher daily physical activity levels may facilitate pre-diabetes regression to normoglycemia: a longitudinal study among an Iranian population. Prev Med Rep. 2023;34:102233. https://doi.org/10.1016/j.pmedr.2023.102233.CrossRefPubMedPubMedCentral

17.

Azizi F, Zadeh-Vakili A, Takyar M. Review of rationale, design, and initial findings: Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018;16(4 Suppl):e84777. https://doi.org/10.5812/ijem.84777.CrossRefPubMedPubMedCentral

18.

Naseri P, Amiri P, Masihay-Akbar H, Jalali-Farahani S, Khalili D, Azizi F. Long-term incidence of cardiovascular outcomes in the middle-aged and elderly with different patterns of physical activity: Tehran Lipid and Glucose Study. BMC Public Health. 2020;20(1):1–10. https://doi.org/10.1186/s12889-020-09747-6.CrossRef

19.

Sheikholeslami S, Ghanbarian A, Azizi F. The impact of physical activity on non-communicable diseases: findings from 20 years of the Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018;16(4 Suppl):e84740. https://doi.org/10.5812/ijem.84740.CrossRefPubMedPubMedCentral

20.

Askari S, Asghari G, Ghanbarian A, Khazan M, Alamdari S, Azizi F. Seasonal variations of blood pressure in adults: Tehran Lipid and Glucose Study. Arch Iranian Med. 2014;17(6):441–3 014176/aim.0012.

21.

Momenan AA, Delshad M, Sarbazi N, Rezaei Ghaleh N, Ghanbarian A, Azizi F. Reliability and validity of the Modifiable Activity Questionnaire (MAQ) in an Iranian urban adult population. Arch Iran Med. 2012;15(5):279–82. https://doi.org/10.4103/2008-7802.151433.CrossRefPubMed

22.

Tohidi M, Ghasemi A, Hadaegh F, Derakhshan A, Chary A, Azizi F. Age- and sex-specific reference values for fasting serum insulin levels and insulin resistance/sensitivity indices in healthy Iranian adults: Tehran Lipid and Glucose Study. Clin Biochem. 2014;47(6):432–8. https://doi.org/10.1016/j.clinbiochem.2014.02.007.CrossRefPubMed

23.

American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes care. 2021;44(Suppl 1):S15–33. https://doi.org/10.2337/dc21-S002.CrossRef

24.

Alizadeh Z, Baradaran HR, Kohansal K, Hadaegh F, Azizi F, Khalili D. Are the determinants of the progression to type 2 diabetes and regression to normoglycemia in the populations with pre-diabetes the same? Front Endocrinol. 2022;13:1041808. https://doi.org/10.3389/fendo.2022.1041808.CrossRef

25.

Hosmer DW, Lemeshow S, Cook E: Applied logistic regression 2nd edition, https://doi.org/10.1002/9781118548387: John Wiley & Sons, Inc.; 2013.

26.

Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690–1. https://doi.org/10.1001/jama.280.19.1690.CrossRefPubMed

27.

Faerch K, Borch-Johnsen K, Holst JJ, Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia. 2009;52(9):1714–23. https://doi.org/10.1007/s00125-009-1443-3.CrossRefPubMed

28.

Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia. 2007;50(6):1127–39. https://doi.org/10.1007/s00125-007-0640-1.CrossRefPubMed

29.

Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 2000;23(8):1067–71. https://doi.org/10.2337/diacare.23.8.1067.CrossRefPubMed

30.

Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999;22(6):908–12. https://doi.org/10.2337/diacare.22.6.908.CrossRefPubMed

31.

Kim EH, Kim HK, Lee MJ, Bae SJ, Choe J, Jung CH, Kim CH, Park JY, Lee WJ. Sex differences of visceral fat area and visceral-to-subcutaneous fat ratio for the risk of incident type 2 diabetes mellitus. Diabetes Metab J. 2022;46(3):486–98. https://doi.org/10.4093/dmj.2021.0095.CrossRefPubMed

32.

Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Ectopic fat obesity presents the greatest risk for incident type 2 diabetes: a population-based longitudinal study. Int J Obes (2005). 2019;43(1):139–48. https://doi.org/10.1038/s41366-018-0076-3.CrossRef

33.

Yamazaki H, Tauchi S, Machann J, Haueise T, Yamamoto Y, Dohke M, Hanawa N, Kodama Y, Katanuma A, Stefan N, et al. Fat distribution patterns and future type 2 diabetes. Diabetes. 2022;71(9):1937–45. https://doi.org/10.2337/db22-0315.CrossRefPubMed

34.

Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes. 2004;28(4):S12–21. https://doi.org/10.1038/sj.ijo.0802853.CrossRef

35.

Appari M, Channon KM, McNeill E. Metabolic regulation of adipose tissue macrophage function in obesity and diabetes. Antioxid Redox Signal. 2018;29(3):297–312. https://doi.org/10.1089/ars.2017.7060.CrossRefPubMedPubMedCentral

36.

Sung HK, Doh KO, Son JE, Park JG, Bae Y, Choi S, Nelson SML, Cowling R, Nagy K, Iacovos MP, et al. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab. 2013;17(1):61–72. https://doi.org/10.1016/j.cmet.2012.12.010.CrossRefPubMed

37.

Spencer M, Unal R, Zhu B, Rasouli N, McGehee RE Jr, Peterson CA, Kern PA. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab. 2011;96(12):E1990-1998. https://doi.org/10.1210/jc.2011-1567.CrossRefPubMedPubMedCentral

38.

Pasarica M, Gowronska-Kozak B, Burk D, Remedios I, Hymel D, Gimble J, Ravussin E, Bray GA, Smith SR. Adipose tissue collagen VI in obesity. J Clin Endocrinol Metab. 2009;94(12):5155–62. https://doi.org/10.1210/jc.2009-0947.CrossRefPubMedPubMedCentral

39.

Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, Peterson CA, Kern PA. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab. 2010;299(6):E1016-1027. https://doi.org/10.1152/ajpendo.00329.2010.CrossRefPubMedPubMedCentral

40.

Rasouli N. Adipose tissue hypoxia and insulin resistance. J Investig Med. 2016;64(4):830–2. https://doi.org/10.1136/jim-2016-000106.CrossRefPubMed

41.

Mazzatti D, Lim F-L, O’Hara A, Wood IS, Trayhurn P. A microarray analysis of the hypoxia-induced modulation of gene expression in human adipocytes. Arch Physiol Biochem. 2012;118(3):112–20.CrossRefPubMed

42.

Lee MW, Lee M, Oh KJ. Adipose tissue-derived signatures for obesity and type 2 diabetes: Adipokines, Batokines and MicroRNAs. J Clin Med. 2019;8(6):854. https://doi.org/10.3390/jcm8060854.CrossRefPubMedPubMedCentral

43.

Koh EH, Park JY, Park HS, Jeon MJ, Ryu JW, Kim M, Kim SY, Kim MS, Kim SW, Park IS, et al. Essential role of mitochondrial function in adiponectin synthesis in adipocytes. Diabetes. 2007;56(12):2973–81. https://doi.org/10.2337/db07-0510.CrossRefPubMed

44.

Choo HJ, Kim JH, Kwon OB, Lee CS, Mun JY, Han SS, Yoon YS, Yoon G, Choi KM, Ko YG. Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia. 2006;49(4):784–91. https://doi.org/10.1007/s00125-006-0170-2.CrossRefPubMed

45.

Guglielmi V, Cardellini M, Cinti F, Corgosinho F, Cardolini I, D’Adamo M, Zingaretti MC, Bellia A, Lauro D, Gentileschi P, et al. Omental adipose tissue fibrosis and insulin resistance in severe obesity. Nutr Diabetes. 2015;5(8):e175–e175. https://doi.org/10.1038/nutd.2015.22.CrossRefPubMedPubMedCentral

46.

Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–77. https://doi.org/10.1038/nrm2391.CrossRefPubMedPubMedCentral

47.

Colleluori G, Perugini J. From obesity to diabetes: the role of the adipose organ. Handb Exp Pharmacol. 2022;274:75–92. https://doi.org/10.1007/164_2021_572.CrossRefPubMed

48.

Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315. https://doi.org/10.1016/j.biopha.2021.111315.CrossRefPubMed

49.

Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375-c391. https://doi.org/10.1152/ajpcell.00379.2020.CrossRefPubMed

50.

Santoro A, Kahn BB. Adipocyte regulation of insulin sensitivity and the risk of type 2 diabetes. N Engl J Med. 2023;388(22):2071–85.CrossRefPubMed

51.

Koloverou E, Panagiotakos DB, Kyrou I, Stefanadis C, Chrysohoou C, Georgousopoulou EN, Skoumas I, Tousoulis D, Pitsavos C. group tAS: Visceral adiposity index outperforms common anthropometric indices in predicting 10-year diabetes risk: results from the ATTICA study. Diabetes Metab Res Rev. 2019;35(6): e3161. https://doi.org/10.1002/dmrr.3161.CrossRefPubMed

52.

Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HFJD. Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory. Diabetes. 2002;51(5):1319–36. https://doi.org/10.2337/diabetes.51.5.1319.CrossRefPubMed

53.

Qatanani M, Lazar MAJG. development: mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21(12):1443–55. https://doi.org/10.1101/gad.1550907.CrossRefPubMed

54.

Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87(2):507–20. https://doi.org/10.1152/physrev.00024.2006.CrossRefPubMed

55.

Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein SJD. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56(4):1010–3. https://doi.org/10.2337/db06-1656.CrossRefPubMed

56.

Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest. 2002;32:14–23. https://doi.org/10.1046/j.1365-2362.32.s3.3.x.CrossRefPubMed

57.

Bergmann K, Sypniewska G. Medicine L: Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? Clin Chem Lab Med. 2013;51(1):177–85. https://doi.org/10.1515/cclm-2012-0490.CrossRefPubMed

58.

Sonoli S, Shivprasad S, Prasad C, Patil A, Desai P, Somannavar MS. Visfatin-a review. Eur Rev Med Pharmacol Sci. 2011;15(1):9–14 PMID: 21381495.PubMed

59.

Heo YJ, Choi S-E, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ. Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes. J Diabetes Res. 2019;2019:4021623. https://doi.org/10.1155/2019/4021623.CrossRefPubMedPubMedCentral

60.

Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Charalampidis P, Livadas S, Kollias A, Sabico SL, Chrousos GP. Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances. Eur J Clin Invest. 2013;43(2):183–9. https://doi.org/10.1111/eci.12030.CrossRefPubMed

61.

Ciresi A, Amato MC, Pizzolanti G, Giordano Galluzzo C. Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. J Clin Endocrinol Metab. 2012;97(8):2907–15. https://doi.org/10.1210/jc.2012-1518.CrossRefPubMed

62.

Zhang M, Zheng L, Li P, Zhu Y, Chang H, Wang X, Liu W, Zhang Y, Huang G. 4-year trajectory of visceral adiposity index in the development of type 2 diabetes: a prospective cohort study. Ann Nutr Metab. 2016;69(2):142–9. https://doi.org/10.1159/000450657.CrossRefPubMed

63.

Yang J, Wang F, Wang J, Han X, Hu H, Yu C, Yuan J, Yao P, Miao X, Wei S, et al. Using different anthropometric indices to assess prediction ability of type 2 diabetes in elderly population: a 5 year prospective study. BMC Geriatr. 2018;18(1):218. https://doi.org/10.1186/s12877-018-0912-2.CrossRefPubMedPubMedCentral

64.

Wang Y, He S, He J, Wang S, Liu K, Chen X. Predictive value of visceral adiposity index for type 2 diabetes mellitus: a 15-year prospective cohort study. Herz. 2015;40(Suppl 3):277–81. https://doi.org/10.1007/s00059-014-4175-1.CrossRefPubMed

65.

Liu PJ, Ma F, Lou HP, Chen Y. Visceral adiposity index is associated with pre-diabetes and type 2 diabetes mellitus in Chinese adults aged 20–50. Ann Nutr Metab. 2016;68(4):235–43. https://doi.org/10.1159/000446121.CrossRefPubMed

Title: Severity of adipose tissue dysfunction is associated with progression of pre-diabetes to type 2 diabetes: the Tehran Lipid and Glucose Study
Authors: Mohammad Jalali
Zahra Bahadoran
Parvin Mirmiran
Fereidoun Azizi
Farhad Hosseinpanah
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Type 2 Diabetes
Prediabetes
Obesity
Obesity
Published in: BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI: https://doi.org/10.1186/s12889-023-17381-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Severity of adipose tissue dysfunction is associated with progression of pre-diabetes to type 2 diabetes: the Tehran Lipid and Glucose Study

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

COVID-19 vaccine hesitancy: assessing the prevalence, predictors, and effectiveness of a community pharmacy based counseling intervention

Clusters of lifestyle behavioral risk factors and their associations with depressive symptoms and stress: evidence from students at a university in Finland

Malaria infection and predictor factors among Chadian nomads’ children

Prevalence and predictors of self-reported hearing aid use and benefit in Norway: the HUNT study

Social determinants of health during and after coronavirus: a qualitative study

Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective